title: Treating moderate to severe psoriasis - best use of biologics.
abstract: This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics.
authors.affiliation: Dermatology Department, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
authors.forename: Maeve
authors.initials: M
authors.lastname: Lynch
authors.forename: Brian
authors.initials: B
authors.lastname: Kirby
authors.forename: Richard B
authors.initials: RB
authors.lastname: Warren
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001691:Biological Therapy / Q000379:methods*; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D006801:Humans; D020381:Interleukin-17 / Q000276:immunology; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000628:therapy*; D053722:Receptors, Interleukin-17 / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D020381:Interleukin-17; D053722:Receptors, Interleukin-17